CAM-FAP-Ac-225 is a best-in-class radiopharmaceutical that combines a fibroblast activation protein (FAP)-targeting single domain antibody targeting vector, with the potent alpha-emitting isotope Actinium-225. FAP is highly expressed in cancerassociated fibroblasts (CAFs) across a broad range of epithelial tumors, making it a promising target for broad therapeutic application.
“This IND submission marks a major milestone for Precirix and our mission to develop innovative and highly targeted cancer therapies” said Tom Piltz, Chief Executive Officer of Precirix. “We are excited to advance CAM-FAP-Ac-225 into clinical development and believe that it has potential to set a new standard for FAP-directed radiopharmaceuticals”.
Following FDA clearance, the company plans to initiate a Phase 1 clinical trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CAM-FAP-Ac225 in patients with advanced solid tumors known to express FAP.
About CAM-FAP-Ac-225
CAM-FAP-Ac-225 is an investigational targeted alpha therapy that delivers Actinium225 directly to the tumor microenvironment via a FAP-targeting ligand. The alpha particles emitted by Ac-225 have high linear energy transfer (LET), enabling potent and localized cytotoxicity with minimal off-target effects.
About Precirix
Precirix is a private biopharmaceutical company dedicated to extending and improving the lives
of cancer patients by designing and developing precision radiopharmaceuticals, using camelid
single domain antibodies (sdAb) labelled with a variety of radioisotopes.
Contact:
Precirix NV
Tom Plitz, CEO
tom.plitz@precirix.com
info@precirix.com
http://www.precirix.com
